MRC1 and neoplasm: Activation of MAPK signalling and downstream targets such as macrophage-expressing arginase 1 (ARG1) and mannose receptor C type 1 (MRC1) in TAMs leads to phenotypic and metabolic adaptation.124,125 This exemplifies how the anti-tumour activity is impaired in the TME by metabolic insufficiency.